Rohtak News Magazine

DelveInsight Business Research LLP

DelveInsight’s ‘Menkes Disease Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Menkes Disease, historical and forecasted epidemiology as well as the Menkes Disease market trends in the G11 i.e. United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Australia, New Zealand, China, and South Korea.

The Menkes Disease market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted G11 Menkes Disease market size from 2019 to 2032. The Report also covers current Menkes Disease treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Some of the key facts of the Menkes Disease Market Report:

• The total diagnosed prevalent cases of Menkes Disease in the G11 were found to be 265 in 2021

• In 2021, the total Menkes Disease market size was USD 0.2 Million which is expected to rise during the study period (2019–2032).

• Menkes Disease companies working in the market are – Cyprium Therapeutics and Sentynl Therapeutics, and others

Key Benefits of the Menkes Disease Report:

• The report covers the descriptive overview of Menkes Disease, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.

• Comprehensive insight has been provided into Menkes Disease epidemiology and treatment.

• Additionally, an all-inclusive account of both the current and emerging therapies for Menkes Disease is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

• A detailed review of the Menkes Disease market; historical and forecasted is included in the report, covering the G11 drug outreach.

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the G11 Menkes Disease market.

Got queries? Click here to learn more about the Menkes Disease Market Landscape

Menkes Disease Overview

Menkes disease is a lethal infantile neurodegenerative disorder with X-linked inheritance. It is an inherited X-linked recessive disorder caused by mutations in the ATP7A gene that is responsible for the transport of copper throughout the body. The mutation could lead to premature birth and may have non-specific symptoms such as hypothermia, hypoglycemia, and prolonged jaundice. These non-specific clinical and biochemical findings could result in the misdiagnosis of neonatal Menkes disease.

Menkes disease is usually inherited, which means it runs in families. The gene is on the X-chromosome, so if a mother carries the defective gene, each of her sons has a 50% (1 in 2) chance of developing the disease, and 50% of her daughters will be a carrier of the disease. The symptoms may not appear in infants until two to three months after birth.

Symptoms of Menkes disease begin shortly after birth and may vary from person to person. The typical symptoms usually start by two months with characteristic skin and hair findings. Sagging facial features, micrognathia, cutis laxa, and blue iris can be noted. Congenital malformations have been reported, including congenital micro ablepharia, entropion, long-arched palate, cerebellar hypoplasia, cystic changes in the lungs, and complete AV block. Neurological manifestations are the most common and characteristic of Menkes disease. Developmental regression and seizures are usually the first to start around 2–3 months.

Occipital horn syndrome is a milder allelic variant of Menkes disease. ATP7A-related distal motor neuropathy is another identified allelic variant that involves a gradual, adult-onset distal motor neuropathy resembling Charcot–Marie–Tooth disease type 2.

Menkes Disease Epidemiological Insights:

• The incidence of Menkes disease in Denmark, France, The Netherlands, the United Kingdom, and West Germany, is based on known Menkes patients born during the time period 1976-87.

• Considering live-born Menkes patients, the combined incidence for these five countries is 1 Menkes patient per 298,000 live-born babies. If the number of affected aborted fetuses is taken into account, the incidence is 1 Menkes per 254,000 live-born babies. 

• This incidence, which is 2-4 times lower than earlier published incidence figures, places Menkes disease as an extremely rare disease. 

• The mutation rate for Menkes disease is estimated to be 1.96 x 10(-6), based on the number of isolated Menkes cases born during the time period 1976-87 and the total number of newborn males during this time.

Menkes Disease Epidemiological Segmentation 

• Total Menkes Disease diagnostic cases 

• Total Menkes Disease treatment cases 

• Total Menkes Disease effect of mutation on the phenotype 

Menkes Disease Market Outlook 

Disorders of copper homeostasis are currently recognized across the life span. Their recognition and links to human disease have spanned several decades, beginning with the recognition of a degenerative disorder in the offspring of sheep grazing in copper-deficient pastures, through to the description of infants suffering from a progressive neurodegenerative disorder characterized by epileptic seizures, developmental regression, failure to thrive, and an unusual hair quality (giving the condition its distinctive label of kinky hair disease)

The current scenario allows treatment of neonatal Menkes patients with copper-histidine (before 30 days of life) for asymptomatic boys with a molecular or biochemical diagnosis, while for patients diagnosed with the disease after 30 days of life is not suggested.

According to DelveInsight, the Menkes Disease treatment paradigm in the G11 is expected to change during the forecasted period 2022–2032.

Learn more by requesting for sample @ Menkes Disease Market Trends

Menkes Disease Key Companies

• Cyprium Therapeutics 

• Sentynl Therapeutics

• And others.

 Menkes Disease Therapies

• CUTX-10

• And others.

Table of Contents

1. Key Insights 

2. Report Introduction 

3. Executive Summary of Menkes Disease     

4. Disease Background and Overview

5. Epidemiology and patient population

6. Menkes Disease   Emerging Therapies

7. Menkes Disease   Market Outlook

8. Market Access and Reimbursement of Therapies

9. Appendix

10. Menkes Disease   Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

Click here to read more about  Menkes Disease Market Insight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/